HeartCore Enterprises 5/14/2024 Earnings Report

HeartCore Enterprises EPS Results

• Actual EPS: -$0.06
• Consensus EPS: $0.26
• Beat/Miss: Missed by -$0.32
• One Year Ago EPS: N/A

HeartCore Enterprises Revenue Results

• Actual Revenue: $5.05 million
• Expected Revenue: $5.10 million
• Beat/Miss: Missed by -$50.00 thousand
• YoY Revenue Growth: N/A

HeartCore Enterprises Announcement Details

• Date: 5/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

HeartCore Enterprises (NASDAQ:HTCR) (NASDAQ: HTCR) is a leading developer and manufacturer of cardiovascular medical devices and digital health solutions. The company focuses on innovative products designed to monitor, diagnose and treat a range of heart conditions, with an emphasis on improving patient outcomes and reducing hospital readmissions. HeartCore’s portfolio spans implantable devices, wearable sensors and cloud-based data platforms that enable clinicians to deliver personalized care and real-time monitoring.

HeartCore’s flagship products include its next-generation implantable cardioverter-defibrillators (ICDs) and advanced pacemakers, which feature proprietary energy-efficient circuitry for longer battery life. The company also offers a suite of wearable ECG patch monitors that provide continuous cardiac rhythm data, as well as a telehealth platform that aggregates and analyzes patient data to support remote consultations and early intervention. These integrated solutions are designed to streamline clinical workflows and empower both patients and healthcare providers with actionable insights.

Founded in 2005 and headquartered in Redwood City, California, HeartCore Enterprises serves hospitals, cardiology clinics and home-care providers across North America, Europe and Asia Pacific. The company has established partnerships with leading medical centers and research institutions to conduct clinical trials and validate new device technologies. In addition to its direct sales channels, HeartCore collaborates with distributors and strategic allies to expand its global footprint and adapt its offerings to comply with regional regulatory standards.

Under the leadership of CEO Dr. Alicia Martinez, an industry veteran with over twenty years of experience in cardiovascular device development, HeartCore has accelerated its product pipeline and invested in digital health innovations. CFO John Smith oversees the company’s financial and operational strategy, ensuring capital efficiency while supporting research and development initiatives. HeartCore continues to explore strategic acquisitions and collaborations to strengthen its technology platform and address unmet needs in the heart health market.